| Literature DB >> 36254239 |
Nianchen Han1, Fan Yang1, Xianghe Zhang1.
Abstract
Background: Despite guidelines provided by the Brain Trauma Foundation (BTF) for treating patients with TBI, including advice to monitor intracranial pressure (ICP), the clinical application of ICP monitoring is far from universal. This laxity has been attributed to the relationship between mortality in TBI patients and ICP monitoring. Objective: This systematic review and meta-analysis was aimed at determining the effect of intracranial pressure (ICP) monitoring on the mortality of patients with traumatic brain injury (TBI). Method: A systematic search for articles was conducted on PubMed, Scopus, Cochrane Central Register of Control Trials (CENTRAL), and APA PsycNet for articles published from 1 January 2000 to 1 August 2022. Manager 5.4 was used to carry out statistical analysis.Entities:
Mesh:
Year: 2022 PMID: 36254239 PMCID: PMC9569199 DOI: 10.1155/2022/1956908
Source DB: PubMed Journal: Comput Math Methods Med ISSN: 1748-670X Impact factor: 2.809
Search strings.
| Database | Search string |
|---|---|
| PubMed/APA PsycNet | (“intracranial pressure monitoring” OR “ICP monitor”) AND (TBI OR “traumatic brain injury” OR “craniocerebral trauma” OR “brain trauma” OR “intracranial pressure”) AND (mortality OR death) |
| Scopus | TITLE-ABS-KEY ((“intracranial pressure monitoring” OR “ICP monitor”) AND (tbi OR “traumatic brain injury” OR “craniocerebral trauma” OR “brain trauma” OR “intracranial pressure”) AND (mortality OR death)) AND PUBYEAR >1999 AND PUBYEAR >1999 |
| CENTRAL | (“intracranial pressure monitoring” OR “ICP monitor”) AND (TBI OR “traumatic brain injury” OR “craniocerebral trauma” OR “brain trauma” OR “intracranial pressure”) AND (mortality OR death) in Title Abstract Keyword - with Cochrane Library publication date Between Jan 2000 and Jan 2022 (Word variations have been searched) |
Note: a date filter from 2000 to 2022 was applied when searching the databases.
Quality assessment criteria.
| Quality criteria | Interpretation |
|---|---|
| Abstract | The abstract is well summarized and informative of what was done in the study |
| Objective | The study objective is clearly stated and leaves no room for misinterpretation |
| Study design and setting | There is a clear elaboration of how the study was done, including location, dates, exposures, and intervention |
| Study variables | All outcomes, exposures, factors, and confounding factors are well identified and clearly defined |
| Statistical methods | There is a clear definition of how quantitative data was handled and the tools used (if any) |
| Results | The provided study results should be relevant to the research question |
| Limitations | The authors established any study limitations encountered |
Figure 1Admission emergency evaluation.
Figure 2PRISMA flowchart.
Figure 3Emergency evaluation associations with mortality.
Quality appraisal.
| Study | Assessment item | ||||||
|---|---|---|---|---|---|---|---|
| Abstract | Objective | Study design | Study variables | Statistical methods | Results | Limitations | |
| Ahl et al. [ | ● | ● | ● | ● | ● | ● | ● |
| Al Saiegh et al. [ | ● | ● | ● | ● | ● | ● | ● |
| Alali et al. [ | ● | ● | ● | ◌ | ● | ● | ◌ |
| Barami et al. [ | ● | ● | ● | ● | ● | ● | ◌ |
| Dawes et al. [ | ● | ● | ● | ● | ● | ● | ● |
| Delaplain et al. [ | ● | ● | ◌ | ◌ | ● | ● | ◌ |
| Farahvar et al. [ | ● | ● | ● | ● | ● | ● | ● |
| Gao et al. [ | ● | ● | ● | ◌ | ● | ● | ● |
| Haddad et al. [ | ● | ● | ● | ● | ● | ● | ● |
| Lane et al. [ | ● | ● | ● | ● | ● | ● | ● |
| MacLaughlin et al. [ | ● | ● | ● | ◌ | ● | ● | ◌ |
| Mauritz et al. [ | ● | ● | ◌ | ● | ● | ● | ● |
| Mauritz et al. [ | ● | ● | ● | ● | ● | ● | ● |
| Piccinini et al. [ | ● | ● | ● | ● | ● | ● | ◌ |
| Rahmanian et al. [ | ● | ● | ● | ● | ● | ● | ● |
| Robba et al. [ | ● | ● | ● | ● | ● | ● | ● |
| Rønning et al. [ | ◌ | ● | ● | ● | ● | ● | ● |
| Shafi et al. [ | ● | ● | ● | ● | ● | ● | ● |
| Talving et al. [ | ● | ● | ● | ◌ | ● | ● | ● |
| Thompson et al. [ | ◌ | ● | ● | ● | ● | ● | ● |
| You et al. [ | ● | ● | ● | ◌ | ● | ● | ◌ |
| Yuan, Wu, Yu, et al., [ | ● | ● | ● | ● | ● | ● | ◌ |
| Zeng et al. [ | ● | ● | ● | ● | ● | ● | ● |
Note: full circle (●) means the assessment item is clearly stated, and an empty circle (○) means that the item is not stated, while a dotted circle (◌) means that the item is unclearly stated.
Study demographics.
| Author and year | Study design | Study region | No. of patients | Inclusion criteria |
|---|---|---|---|---|
| Ahl et al. [ | Retrospective observational cohort study | USA | 1154 | Abbreviated injury scale (AIS) head of ≥3 and Glasgow coma scale (GCS) of ≤8 |
| Al Saiegh et al. [ | Retrospective observational cohort study | USA | 36929 | GCS < 9 |
| Alali et al. [ | Retrospective cohort study | US, Canada | 10628 | AIS head > 3 and GCS < 9 satisfy BTF criteria for ICP monitoring |
| Barami et al. [ | Retrospective cohort study | US | 199 | GCS < 9, age ≥ 18 years |
| Dawes et al. [ | Retrospective cohort study | US | 822 | Blunt injury, GCS ≤ 8, and abnormal intracranial findings on head computed tomography (CT) |
| Delaplain et al. [ | Retrospective cohort study | US | 3808 | Age ≤ 16 years, GCS ≤ 8 |
| Farahvar et al. [ | Retrospective cohort study | USA | 1307 | GCS < 9 |
| Gao et al. [ | Retrospective cohort study | China | 36 | AIS head > 3 and GCS < 9 satisfy BTF criteria for ICP monitoring |
| Haddad et al. [ | Retrospective cohort study | Saudi Arabia | 477 | GCS < 9 |
| Lane et al. [ | Retrospective cohort study | Canada | 5487 | AIS head > 3 |
| MacLaughlin et al. [ | Retrospective observational cohort study | USA | 123 | GCS ≤ 8 with intracranial hemorrhage |
| Mauritz et al. [ | Retrospective observational cohort study | Austria | 415 | GCS < 9 |
| Mauritz et al. [ | Observational cohort study | Austria | 1856 | GCS < 9 |
| Piccinini et al. [ | Retrospective cohort study | USA | 4880 | AIS > 3, GCS < 9 |
| Rahmanian et al. [ | Retrospective cohort study | Iran | 120 | Age ≥ 18 years, GCS ≤ 8 |
| Robba et al. [ | Prospective observational cohort study | International (42 countries) | 2367 | Age ≥ 18 years, GCS eye response score of 1 (no eye opening), and GCS motor response score ≤ 5 (not obeying commands) |
| Rønning et al. [ | Retrospective observational cohort study | Norway | 1327 | Age ≥ 12 years, GCS < 9, and AIS scores ≥ 2 |
| Shafi et al. [ | Retrospective cohort study | USA | 1646 | GCS < 9 |
| Talving et al. [ | Prospective cohort study | USA | 216 | AIS head > 3 and GCS < 9 satisfy BTF criteria for ICP monitoring |
| Thompson et al. [ | Retrospective observational cohort | USA | 4251 | Age 24–65 yrs, ICD-9 code |
| You et al. [ | Observational, prospective cohort study | China | 166 | Age ≥ 65 years, GCS < 9 |
| Yuan, Wu, Yu, et al., [ | Retrospective observational multicenter study | China | 1676 | Age > 14 years, GCS ≤ 12 |
| Zeng et al. [ | Prospective cohort study | China | 168 | GCS < 12 |
Partial clinical data statistics.
| Total | 69.299 (100.0) | 2240 (3.2) | 33,327 (100.0) |
|---|---|---|---|
| Male | 31.601 (45.6) | 1090 (3.4) | 15,297 (45.9) |
| Age (y) (mean (SD)) | 70.7 (11.7) | 70.4 (11.9) | |
| M54 | 6934 (10.0) | 67 (1.0) | 3697 (11.1) |
| 55-64 | 13.461 (19.4) | 259 (1.9) | 6613 (19.8) |
| 65-74 | 19,765 (28.5) | 618 (3.1) | 9422 (28.3) |
| 75-84 | 21.609 (31.2) | 911 (4.2) | 9776 (29.3) |
| 285 | 7530 (10.9) | 385 (5.1) | 3819 (11.5) |
| Laboratory results | |||
| Blood urea nitrogen (>40 mg/dL) | 4474 (6.5) | 477 (10.7) | 2108 (6.3) |
| Blood urea nitrogen (31-40 mg/dL) | 5097 (7.4) | 312 (6.1) | 2485 (7.5) |
| Blood urea nitrogen (26-30 mg/dL) | 5329 (7.7) | 254 (4.8) | 2591 (7.8) |
| pH arterial (§7.30) | 5966 (8.6) | 655 (11.0) | 2917 (8.8) |
| Albumin (2.4 g/dL) | 948 (1.4) | 128 (13.5) | 542 (1.6) |
| Albumin (2.5-3.0 g/dL) | 4315 (6.2) | 295 (6.8) | 2274 (6.8) |
| White blood cell (>19.8 k/mm3) | 3469 (5.0) | 283 (8.2) | 1576 (4.7) |
| White blood cell (14.2-19.8 k/mm3) | 8587 (12.4) | 409 (4.8) | 4082 (12.2) |
| White blood cell (10.9-14.1 k/mm3) | 13,031 (18.8) | 457 (3.5) | 6414 (19.2) |
| Creatine phosphokinase (M35 or >500 U/L) | 8670 (12.5) | 469 (5.4) | 4280 (12.8) |
| PO (50 or >140 mm Hg) | 5047 (7.3) | 437 (8.7) | 2305 (6.9) |
| Sodium (£135 or >145 mEq/L) | 17.115 (24.7) | 729 (4.3) | 8067 (24.2) |
| Hemoglobin (£11 or>18 g/dL) | 10,700 (15.4) | 649 (6.1) | 5554 (16.7) |
| Potassium (>4.9 mEq/L) | 5955 (8.6) | 476 (8.0) | 2859 (8.6) |
| Prothrombin time > 14 s or PT international normalized ratio > 1.2 | 12,168 (17.6) | 640 (5.3) | 6364 (19.1) |
| Bands (>32%) | 589 (0.8) | 58 (9.8) | 276 (0.8) |
| Platelets (115 × 109/L) | 2312 (3.3) | 140 (6.1) | 1164 (3.5) |
| Vital signs and altered mental status (AMS) | |||
| Pulse (M49 or >129/min) | 7051 (10.2) | 529 (7.5) | 3192 (9.6) |
| Pulse (120-129/min) | 6459 (9.3) | 274 (4.2) | 2930 (8.8) |
| Pulse (100-119/min) | 22.872 (33.0) | 717 (3.1) | 10.861 (32.6) |
| Oral temperature (<95 F) | 826 (1.2) | 75 (9.1) | 300 (0.9) |
| Respirations (>39/min) | 4101 (5.9) | 297 (7.2) | 1842 (5.5) |
| Respirations (30-39/min) | 13,044 (18.8) | 653 (5.0) | 5818 (17.5) |
| Systolic blood pressure (£99 mm Hg) | 6029 (8.7) | 438 (7.3) | 2887 (8.7) |
| Severe AMS | 1728 (2.5) | 344 (19.9) | 770 (2.3) |
| Mild or moderate AMS | 7044 (10.2) | 538 (7.6) | 3632 (10.9) |
| Major comorbiditics (sorted by prevalence) | |||
| Hypertension | 38.165 (55.1) | 1151 (3.0) | 19.462 (58.4) |
| Congestive heart failure | 18.679 (27.0) | 1080 (5.8) | 9460 (28.4) |
| Diabetes without chronic complications | 17,055 (24.6) | 509 (3.0) | 8762 (26.3) |
| Depression | 10.158 (14.7) | 264 (2.6) | 5395 (16.2) |
| Deficiency anemias | 10.032 (14.5) | 531 (5.3) | 5426 (16.3) |
| Peripheral vascular disease | 5961 (8.6) | 242 (4.1) | 2917 (8.8) |
| Renal failure | 4900 (7.1) | 337 (6.9) | 3603 (10.8) |
| Hematologic or solid organ malignancy | 2410 (3.5) | 136 (5.6) | 1230 (3.7) |
| Diabetes with chronic complications | 2379 (3.4) | 107 (4.5) | 1342 (4.0) |
| Pulmonary circulation disease | 1950 (2.8) | 246 (12.6) | 1081 (3.2) |
| Weight loss | 1816 (2.6) | 203 (11.2) | 997 (3.0) |
| Metastatic cancer | 1028 (1.5) | 93 (9.0) | 527 (1.6) |
| Liver disease | 896 (1.3) | 37(4.1) | 514 (1.5) |
Results from subgroups.
| Subgroup | OR |
| Weight |
|---|---|---|---|
| 2000-2010 | 1.70 [0.97, 3.00] | 0.07 | 21.7% |
| 2011-2015 | 0.71 [0.56, 0.91] | 0.007 | 44.2% |
| 2016-present | 1.12 [0.72, 1.73] | 0.62 | 34.1% |
Figure 4Forest plot of comparison: ICP vs. non-ICP.
Figure 5Funnel plot of comparison: ICP vs. non-ICP.
Figure 6Forest plot of comparison: ICP vs. non-ICP.
Figure 7Funnel plot of comparison: ICP vs. non-ICP.